ACAB: Atlantic Coastal Acquisition Corp. II Stock

by  •  • Comments Off on ACAB: Atlantic Coastal Acquisition Corp. II Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 0.00
Enterprise Value ($M) 1.55
Book Value ($M) -15.82
Book Value / Share -1.94
Price / Book 0.00
NCAV ($M) -23.19
NCAV / Share -2.84
Price / NCAV 0.00

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.01
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.85
Current Ratio 0.85

Balance Sheet (mrq) ($M)
Current Assets 29.99
Assets 37.37
Liabilities 53.18
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -1.67
Net Income 2.82
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -3.85
Cash from Investing 278.44
Cash from Financing -274.73

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-07 13G/A Saba Capital Management, L.P. 0.00 -100.00
01-19 13G/A Highbridge Capital Management Llc 0.00 -100.00
2023-04-20 13D Atlantic Coastal Acquisition Management II LLC 65.80

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-04-01 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PUR
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI
2023-12-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2023 ☐ TRANSITION REPORT PURSUA
2023-08-22 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO
2023-05-22 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT T

(click for more detail)

Similar Companies
ACET – Adicet Bio, Inc. ACIU – AC Immune SA


Financial data and stock pages provided by
Fintel.io